• linkedin
  • Increase Font
  • Sharebar

    Factors in prostate Ca decision-making vary by race

    Findings from a population-based cohort study of patients newly diagnosed with prostate cancer show race-related differences in what men perceive as important factors in their treatment decision-making process and also the aggressiveness of their disease.

    In addition, a multivariable analysis adjusting for sociodemographic characteristics found that patients’ perception about cancer aggressiveness was the most important factor associated with the type of treatment received.

    Also see - Prostate Cancer: Studies suggest strategies for marker, mpMRI use

    The study, presented at the American Society of Clinical Oncology annual meeting in Chicago, was conducted by Ronald C. Chen, MD, MPH, and colleagues at the University of North Carolina at Chapel Hill, in collaboration with the North Carolina Central Cancer Registry. It included prospectively collected data from 1,170 men enrolled in the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study between 2011 and 2013.

    “Racial disparities in prostate cancer are well known. Compared to Caucasian patients, African-American patients are more than twice as likely to die from prostate cancer. Part of this disparity may be due to the fact that African-American patients get less aggressive treatment overall,” Dr. Chen told Urology Times.

    “We conducted this study to provide some insights on why there is this racial difference in treatment. To the best of our knowledge, there has not been a large-scale study like it before.”

    Next: Findings "provide new information that can help explain and address the racial difference in treatment for prostate cancer"


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available